Calibrant Biosystems announced a research collaboration with the Yale University School of Medicine to identify novel ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant's Gemini proteomics platform. Calibrant will identify proteins and protein networks involved in ovarian and breast cancer, as well as select novel therapeutic targets found to be central to disease progression.
"Our collaboration with Dr. Tavasolli at Yale University contributes substantially to our gynecologic and breast cancer drug programs," stated Dr. Brian Balgley, Chief Technology Officer of Calibrant Biosystems. "This partnership is enabling effective identification of disease-relevant pathways and drug targets by applying Calibrant's Gemini platform to targeted discovery from selected cancer cells." Dr. Fattaneh Tavasolli, Calibrant's collaborator at the Yale University School of Medicine, is Professor of Pathology and Director of the Women's Health Program/Gynecology and Breast Pathology.
Calibrant has recently established several drug discovery collaborations with world-renowned medical research centers this year, leading to active therapeutic programs for cancer indications including ovarian and primary brain cancer.
About Calibrant Biosystems
Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrant's advanced Gemini discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the unique ability to comparatively map protein networks between different cell types within a single tissue section. With an initial focus on monoclonal antibody drug development in oncology, Calibrant is leveraging the Gemini platform for the development of first-in-class therapeutics across a range of cancer indications. More information is available at calibrant.
Note: Gemini is a trademark of Calibrant Biosystems.
Calibrant Biosystems
Комментариев нет:
Отправить комментарий